
Opinion|Videos|November 4, 2024
Current Practices in B7-H3 Testing
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with SCLC. If B7-H3 testing becomes available, he would consider adding it to the biomarker assay, particularly at the time of diagnosis or recurrence.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Is individual B7-H3 analysis currently available at your institution ?
If so, do you obtain IHC for both PD-L1 and B7-H3 expression levels in all your patients with SCLC?
If not, when IHC and/or PC does become available for B7-H3 testing, would you consider adding it to your biomarker assay?
o At which stage of disease
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5
























